As of 2026-09-17, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (13.01) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -251.1%.
The range of the Relative Valuation is (11.40) - (14.48) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 23.2x - 29.6x | 26.4x |
| Forward P/E multiples | 23.3x - 30.3x | 26.8x |
| Fair Price | (11.40) - (14.48) | (13.01) |
| Upside | -232.3% - -268.1% | -251.1% |
| Date | P/E |